Immunomedics Acquisition Transfers Development of Sacituzumab Govitecan to Gilead Sciences
October 8th 2020
Gilead Sciences’ acquisition of Immunomedics, the manufacturer of sacituzumab govitecan-hziy, is expected to advance the development of the antibody-drug conjugate not only across additional types of breast cancer beyond triple-negative disease, but also in other solid tumors.